Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts

Self Cite

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non‐dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient‐Oriented Outcomes and ARHS recommend the use of the dermatology‐specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea‐specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.

Section: Discussionmentioning

confidence: 99%

“…There are many reasons that HRQoL should be measured. The EADV TF on QoL and Patient‐Oriented Outcomes has previously presented recommendations on the principles of HRQoL instrument selection and their use in different skin diseases 100,112–126 …”

Section: Discussionmentioning

confidence: 99%

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Chernyshov

Finlay

Aragonés

et al. 2023

Self Cite

“…Vitiligo global Impact scale 0 to 10 or 5‐point scale), or with a more comprehensive burden scale [e.g. Vitiligo Impact Patient Scale (VIPs), Vitiligo Quality of Life scale (VitiQOL) and Vitiligo Impact Scale (VIS‐22)] 21,22,28‐33 …”

Section: Assessment Of the Disease Burdenmentioning

confidence: 99%

“…Vitiligo Impact Patient Scale (VIPs), Vitiligo Quality of Life scale (VitiQOL) and Vitiligo Impact Scale (VIS-22)]. 21,22,[28][29][30][31][32][33] Management of the psychological implications of vitiligo is an important aspect of overall disease management. 34 Psychological support includes but is not limited to counselors, psychologists and psychiatrists, and depends on local resources, networking and the extent of the morbidity.…”

Section: Asse Ssm E N T Of Th E Dise Ase Bu R De Nmentioning

confidence: 99%

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm

van Geel,

Speeckaert,

Taïeb

et al. 2023

Self Cite

BackgroundThe treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long‐term approach. To improve the management of vitiligo worldwide, a clear and up‐to‐date guide based on international consensus with uniform stepwise recommendations is needed.ObjectivesTo reach an international consensus on the nomenclature and to develop a management algorithm for the diagnosis, assessment, and treatment of vitiligo.MethodsIn this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence of topics included in the algorithms. A survey was utilized to resolve remaining issues among a core group of eight experts. Subsequently, the unanimous recommendations were finalized and validated based on further input from the entire group during two live meetings.ResultsThe algorithms highlight the importance of shared decision‐making. Dermatologists are encouraged to provide patients with detailed explanations of the prognosis and expected therapeutic outcomes based on clinical examination. The treatment goal should be discussed and clearly emphasized to patients given the different approaches for disease stabilization and repigmentation. The evaluation of disease activity remains a cornerstone in the tailor‐made approach to vitiligo patients.ConclusionsThese new treatment algorithms are intended to guide clinical decision‐making in clinical practice. Promising novel therapies for vitiligo are on the horizon, further highlighting the need for reliable outcome measurement instruments and greater emphasis on shared decision‐making.

“…

Rosacea is a chronic, inflammatory condition that is often accompanied by a stinging or burning sensation and pruritus, which significantly impacts quality of life. 1,2 Rosacea is often treatment-resistant; can frequently be aggravated by physical stimuli during daily activities, such as heat and sun exposure; and is representative of a family of skin diseases that present with a sensitive skin phenotype and are characterized by barrier disruption. 3,4 Demodex mites are naturally found in human pilosebaceous follicles and do not display any beneficial or detrimental effects

…”

mentioning

confidence: 99%

Cutaneous neurogenic inflammation mediated by TRPV1–NGF–TRKA pathway activation in rosacea is exacerbated by the presence of Demodex mites

Lee,

Kim,

Lee

et al. 2023

BackgroundRosacea is a common chronic inflammatory skin condition that is often refractory to treatment, with frequent relapses. Alterations in the skin immunological response and Demodex mite infestation are the primary aetiologic factors targeted for treatment. Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a nociceptive cation channel that plays a role in cutaneous neurogenic pain and can be activated by various rosacea triggers.ObjectivesWe investigated the effects of TRPV1 modulation in rosacea, focussing on Demodex mite colonization and cutaneous neurogenic inflammation.MethodsWe examined mRNA expression levels according to Demodex population counts. An in vitro study using capsazepine as a TRPV1 antagonist was performed to assess the influence of TRPV1 in keratinocytes. A rosacea‐like mouse model was generated by the injection of the 37‐amino acid C‐terminal cathelicidin peptide (LL37), and changes in the skin, dorsal root ganglion (DRG) and ears were examined.ResultsIncreased Demodex mite population counts were associated with increased expression levels of TRPV1, tropomyosin receptor kinase A (TrkA) and nerve growth factor (NGF), and these levels could be reduced by capsazepine treatment in keratinocytes. In an in vivo study, the downstream effects of TRPV1 activation were investigated in the skin, DRG and ears of the rosacea‐like mouse model.ConclusionsThe findings of this study are instrumental for understanding the underlying causes of rosacea and could potentially lead to the development of new treatments targeting the NGF–TrkA–TRPV1 pathway. The identification of this pathway as a therapeutic target could represent a major breakthrough for rosacea research, potentially resulting in more effective and targeted rosacea treatments. This study contributes to an improved understanding of rosacea pathophysiology, which may lead to the development of more effective treatments in the future.